OncoMatch/Clinical Trials/NCT07801287
Iparomlimab/Tuvonralimab Plus SBRT and Lenvatinib for Perioperative Treatment of Potentially Resectable Intermediate-Stage HCC
Is NCT07801287 recruiting? Yes, currently enrolling (Sep 2026). This Phase 2 trial studies Iparomlimab/Tuvonralimab plus SBRT and Lenvatinib for hcc - hepatocellular carcinoma.
Treatment: Iparomlimab/Tuvonralimab plus SBRT and Lenvatinib — This study aims to evaluate the efficacy and safety of Iparomlimab and Tuvonralimab (the combination antibody) combined with SBRT and Lenvatinib in the perioperative treatment of patients with potentially resectable intermediate-stage hepatocellular carcinoma.. The objective is to explore potential survival benefits for this population and provide patients with more effective treatment options.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Targeted therapy
Cancer type
Hepatocellular Carcinoma
Disease stage
Required: Stage IIIA
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Lab requirements
Blood counts
Adequate bone marrow function within 7 days prior to the first administration of study drug
Liver function
Child-Pugh score <7
Child-Pugh score <7; Adequate organ and bone marrow function within 7 days prior to the first administration of study drug
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT07801287 currently recruiting?
Yes, this trial is currently recruiting patients.
Can patients have received prior systemic therapy?
No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.
What disease stage is eligible?
Stage IIIA is required.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages